^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    MIR6836 (MicroRNA 6836)

    i
    Other names: MIR6836, MicroRNA 6836, Hsa-Mir-6836, MicroRNA Mir-6836, MIMAT0027575, MIMAT0027574, MI0022682
    Associations

    News

    Trials
    1year
    Identification of lncRNA-miRNA-mRNA ceRNA axes and KEGG pathways related to uveal melanoma metastasis. (PubMed, Technol Health Care)
    The results showed that the involvement of UM-related Wnt/β-catenin and Chemokine signaling pathways and the ceRNA regulatory axes showed noteworthy interest in UM metastasis.
    Journal
    |
    H19 (H19 Imprinted Maternally Expressed Transcript) • PVT1 (Pvt1 Oncogene) • MAP3K7 (Mitogen-Activated Protein Kinase Kinase Kinase 7) • MIR106B (MicroRNA 106b) • MIR122 (MicroRNA 122) • MIR6836 (MicroRNA 6836) • PLCB4 (Phospholipase C Beta 4) • WNT7B (Wnt Family Member 7B) • MAPK10 (Mitogen-Activated Protein Kinase 10)
    almost2years
    An evolutionary learning-based method for identifying a circulating miRNA signature for breast cancer diagnosis prediction. (PubMed, NAR Genom Bioinform)
    A comprehensive gene-set enrichment analysis was also performed to understand the underlying mechanisms of these target genes. BSig, a tool capable of BC detection and facilitating therapeutic selection, is publicly available at https://github.com/mingjutsai/BSig.
    Journal
    |
    MIR5100 (MicroRNA 5100) • MIR6836 (MicroRNA 6836)
    over2years
    Extracellular vesicles carrying miR-6836 derived from resistant tumor cells transfer cisplatin resistance of epithelial ovarian cancer via DLG2-YAP1 signaling pathway. (PubMed, Int J Biol Sci)
    Furthermore, miR-6836 could be packaged into secreted exosomes in cisplatin-resistant EOC cells and exosomal miR-6836 was able to be delivered into cisplatin-sensitive EOC cells and reverse their cisplatin response. Our study revealed the molecular mechanisms of chemotherapy resistance, and identified miR-6836 as the possible therapeutic target and effective biopsy marker for resistant EOC.
    Journal • Tumor cell
    |
    YAP1 (Yes associated protein 1) • MIR6836 (MicroRNA 6836) • TEAD1 (TEA Domain Transcription Factor 1)
    |
    cisplatin
    over3years
    Construction of a Diagnostic Model for Distinguishing Benign or Malignant Bone Cancer by Mining miRNA Expression Data. (PubMed, Biochem Genet)
    The results were consistent with the trend of miRNAs expression in public databases. In summary, we examined the differential expression of serum miRNAs in individuals with benign and malignant bone tumors and discovered 11 miRNA biomarkers that could be utilized to discriminate between the two.
    Journal
    |
    MIR155 (MicroRNA 155) • MIR142 (MicroRNA 142) • MIR192 (MicroRNA 192) • MIR3187 (MicroRNA 3187) • MIR1205 (MicroRNA 1205) • MIR127 (MicroRNA 127) • MIR6836 (MicroRNA 6836)